Oral 25-hydroxyvitamin D3 and COVID-19
COVID 19
About this trial
This is an interventional prevention trial for COVID 19 focused on measuring COVID 19, Vitamin D, 25-hydroxyvitamin D3, 1,25-dihydroxyvitamin D3, Viral infection, Cytokine storm, supplementation, Clinical Trial, Health Care provider, Prevention, Treatment
Eligibility Criteria
Inclusion Criteria:
- Older than 18 years old and younger than 75 years old for all study groups.
- Meet the diagnostic criteria of COVID-19 for different types (including ordinary type, heavy type and critical type) in infected patients.
- No medications or disorders that would affect vitamin D metabolism
- Women must be on birth control and not pregnant
- Ability and willingness to give informed consent and comply with protocol requirements
Exclusion Criteria:
- Ongoing treatment with pharmacologic doses of vitamin D, vitamin D metabolites or analogues
- Pregnant or lactating women;
- Severe underlying diseases, such as advanced malignant tumors, endstage lung disease, etc.
- History of elevated serum calcium >10.6 mg/dl; that is corrected for albumin concentration or subjects with a history of hypercalciuria and kidney stones.
- Chronic hepatic dysfunction, chronic kidney disease or intestinal malabsorption syndromes including inflammatory bowel disease.
- Supplementation with over the counter formulations of vitamin D2 or vitamin D3
- Use of tanning bed or artificial UV exposure within the last two weeks.
- Consuming medication affecting vitamin D metabolism or absorption (anticonvulsants, anti-tuberculosis medication glucocorticoids, HIV medications and cholestyramine).
- Subjects with a history of an adverse reaction to orally administered vitamin D, vitamin D metabolites or analogues.
- Subjects with a history of conditions that can lead to high serum calcium levels such as sarcoidosis, tuberculosis and some lymphomas associated with activated macrophages which increase the production of 1,25(OH)2D.
- Inability to give informed consent
Sites / Locations
- Tehran University of Medical SciencesRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Treatment
Prevention
Infected patients with acute respiratory tract infection symptoms (e.g. fever, cough, dyspnea) with no other etiology that fully explains the clinical presentation accompanied by chest computed tomography (CT) scan findings compatible with Covid-19 or with a COVID-19 positive test by the polymerase chain reaction (PCR)
This arm of study includes the health care providers and hospital workers with a negative test for COVID-19 and a close patient relative with a negative test for COVID-19 who lives with the infected patients.